Cancer Immunotherapy Co. Scores $62M To Advance Research – Law360
|
Cancer Immunotherapy Co. Scores $62M To Advance Research
Law360 Cancer Immunotherapy Co. Scores $62M To Advance Research. By Matthew Guarnaccia. Law360, New York (December 13, 2017, 7:31 PM EST) — Oncology treatment developer Pionyr Immunotherapeutics Inc. said Wednesday its latest funding round brought in $62 … |
